cagrilintide novo nordisk Stock Rises on Trial Results for Obesity Treatment Novo Nordisk: Can CagriSema Show

A history of regulatory challenges FDA investigators first began documenting problems with Empowers sterile drug production processes in 2015, when the company did not thoroughly investigate how a batch of weight loss injectables became contaminated with bacteria, records say

doi:10.1016/j.jep.2004.07.010 Li Z, Liu J, Zhao Y

Your body doesnt make B12

10.1016/s0196-9781(02)00083-9 41 FuM.YuX.LuJ.ZuoY

An FDA 483 Warning Letter is a formal notice from the Food and Drug Administration that points to serious compliance issues within your facility or operations

That changed in 2023, when the FDA determined that 19 peptides posed significant safety risks and moved them to a de facto do not compound list